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Abstract
The TNF family cytokines BAFF (B-cell activating factor of the TNF family) and APRIL (a proliferation-inducing ligand) are
crucial survival factors for B-cell development and activation. B-cell directed treatments have been shown to improve atopic
eczema (AE), suggesting the involvement of these cytokines in the pathogenesis of AE. We therefore analyzed the
expression of these TNF cytokines in AE, seborrheic eczema (SE) and healthy controls (HC). The serum/plasma concentration
of BAFF, APRIL and a close TNF member TWEAK (TNF-like weak inducer of apoptosis) was measured by ELISA. The
expression of these cytokines and their receptors in skin was analyzed by quantitative RT-PCR and immunofluorescence.
Unlike other inflammatory diseases including autoimmune diseases and asthma, the circulating levels of BAFF, APRIL and
TWEAK were not elevated in AE or SE patients compared with HCs and did not correlate with the disease severity or
systemic IgE levels in AE patients. Interestingly, we found that the expression of these cytokines and their receptors was
altered in positive atopy patch test reactions in AE patients (APT-AE) and in lesional skin of AE and SE patients. The
expression of APRIL was decreased and the expression of BAFF was increased in eczema skin of AE and SE, which could
contribute to a reduced negative regulatory input on B-cells. This was found to be more pronounced in APT-AE, the
initiating acute stage of AE, which may result in dysregulation of over-activated B-cells. Furthermore, the expression levels of
TWEAK and its receptor positively correlated to each other in SE lesions, but inversely correlated in AE lesions. These results
shed light on potential pathogenic roles of these TNF factors in AE and SE, and pinpoint a potential of tailored treatments
towards these factors in AE and SE.
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Introduction
Atopic eczema (AE) is a chronic inflammatory skin disorder and
known to be caused by a combination of multiple factors, including
genetic predisposition, skin barrier dysfunction, immunological
deviation and environmental allergens [1]. Most AE patients have
elevated concentration of total and allergen-specific serum IgE [2].
Some patients also haveIgE against self-antigens, suchas manganese
superoxide dismutase(MnSOD)[2,3].ThelipophilicyeastMalassezia
belongs to the commensal skin microflora, however, it can induce
specific IgE and T-cell reactivity in AE patients [2,3]. Seborrheic
eczema(SE)isanotherchronicinflammatoryskindisorderassociated
with Malassezia reactivity but without IgE production [4].
Although the exact role of B-cells in AE is not fully understood,
the contribution of B-cells to AE etiopathogenesis has become
evident by studies showingthat B-cell-depletingtreatment with anti-
CD20 Ab improved AE skin lesions with reduced mRNA expre-
ssion of IL-5 and IL-13 and decreased infiltration of T and B-cellsin
skin,whereastotalandallergen-specific IgE levelswerenot reduced,
suggesting other functions than Ab production of B-cells in the
disease mechanisms [5]. It has recently become appreciated that
aberrant regulation and activation of B-cells result in chronic
inflammatory and autoimmune-mediated disorders. They contrib-
ute to the disease pathogenesis not only by being the Ab producers,
but also as APCs (antigen-presenting cells) and cytokine/chemokine
producers [6,7]. Accordingly, B-cell directed therapy, including Abs
against B-cell specific markers and inhibitors of survival and
signalling factors for B-cells, is currently introduced for the
treatment of inflammatory and autoimmune diseases [6,7].
The TNF ligand members BAFF (B-cell activating factor of the
TNF family) and APRIL (a proliferation-inducing ligand) are two
crucial survival factors for peripheral B-cells [8]. They can
promote Ab class switching independently of the CD40/CD40L
pathway [8]. BAFF and APRIL are expressed mainly by innate
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well as non-haematopoietic tissue resident cells [8]. BAFF and
APRIL share the receptors TACI (transmembrane activator and
calcium-modulator and cyclophilin ligand interactor) and BCMA
(B-cell maturation antigen). In addition, BAFF binds to BAFFR
and APRIL interacts with heparan sulphate proteoglycans [8].
BAFF is expressed as both surface-bound and soluble factors,
whereas APRIL is processed inside the cell and released as a
soluble protein [8]. However, APRIL can be attached to the cell
surface by being a natural fusion protein with TWEAK (TNF-like
weak inducer of apoptosis), called TWE-PRIL, sharing receptors
with APRIL [9]. Thus, these factors form a network of mediators
interacting with an overlapping set of receptors.
In humans, increased levels of BAFF and/or APRIL in serum
or target tissues have been described in a number of autoimmune
conditions and often correlated to disease progression [8]. In
allergic diseases, so far, an elevated serum level of BAFF has been
suggested as a diagnostic parameter for asthma [10]. In AE, an
increased serum BAFF level in children has been reported [11].
However, another group has published data in adult AE patients
having an elevated serum level of APRIL, but not BAFF [12].
When not fused to APRIL, full length TWEAK is a
multifunctional cytokine, regulating cell proliferation, migration,
differentiation, apoptosis, angiogenesis and inflammation [13],
playing either beneficial or detrimental biological effects in mouse
models, depending on the tissue injury or disease model that is
used [14]. Its receptor Fn14 (Fibroblast growth factor-inducible
14) is expressed by many cell types, but absent on lymphocytes
[13]. The expression of TWEAK and Fn14 is relatively low in
normal tissues and up-regulated by tissue injury or disease [13]. It
has recently been reported that TWEAK and TNF-a can
cooperate in the induction of keratinocyte apoptosis, suggesting
a role of TWEAK in eczema formation of AE [15] . Apart from
this, TWEAK/Fn14 interaction in human keratinocytes has also
been shown to induce the production of the chemokine RANTES,
suggesting the potential involvement of TWEAK/Fn14 in the
pathophysiology of inflammatory skin disorders [16].
To define the role of BAFF, APRIL and TWEAK in
inflammatory skin disease, we characterized their expression in
the circulation and the skin in AE, SE and HC. To get a more
complete picture of the dynamic regulation of these factors,
positive atopy patch test reactions in AE patients (APT-AE) was
included, which mimics the early stage of AE lesions [17,18]. Our
results demonstrate that unlike other inflammatory diseases, the
levels of BAFF, APRIL and TWEAK are not elevated in the
circulation and do not correlate with the severity of AE. Instead,
the levels and expression patterns of these cytokines are changed in
eczema skin of both AE and SE compared to skin of HC, showing
an altered balance in the eczema skin for these TNF members.
Results
Circulating levels of BAFF, APRIL and TWEAK are not
elevated in AE or SE patients
First, we measured plasma/serum levels of BAFF, APRIL and
TWEAK by ELISA. We found that these cytokines were not
elevated in AE or SE patients compared to HC (Fig. 1A–C). When
investigatingsubgroupsofAEpatients(Fig.1D–F),theplasma levels
of BAFF were found to be decreased in patients with severe AE
(Fig. 1D), as well as in the subgroup with elevated total IgE (Fig. 1E).
However, the plasma/serum levels of these cytokines did not
correlate with the SCORAD index or with the plasma levels of total
IgE or Malassezia-specific IgE in AE patients (Table 1). Since the
circulating levels of these factors have been found to be increased in
autoimmune disease [8,13], we analyzed a subgroup of AE patients
to elucidate whether their specific IgE levels to human MnSOD
(n=5) [19] correlated with the circulating levels of these cytokines,
however, no correlation was found (data not shown).
The mRNA expression of BAFF is increased in SE and APT-
AE, but not in AE lesions
To analyze the expression of BAFF, APRIL and TWEAK in
eczema lesions, skin biopsies from AE and SE patients as well as
HC were randomly selected from the respective groups in table 2
Figure 1. Plasma/serum levels of BAFF, APRIL and TWEAK in HC and patients with AE or SE. (A) BAFF, (B) APRIL and (C) TWEAK measured
by ELISA in HC and patients with AE or SE. (D–F) Plasma levels of BAFF in subgroups of AE patients with (D) severe or moderate AE, (E) with/without
increased total plasma IgE and (F) with/without Malassezia (m227)-specific plasma IgE. Data shown as individual patients or healthy controls,
horizontal bar indicates the median, *p,0.05, **p,0.01 by Mann-Whitney test.
doi:10.1371/journal.pone.0022202.g001
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and verified for protein expression by immunofluorescence.
We found that mRNA expression of BAFF was about 10 times
higher in APT-AE and about 7 times higher in SE lesions
compared to HC (Fig. 2A). The mRNA levels of BAFFR and
TACI were decreased in all the inflammatory conditions (Fig. 2B).
Since these two receptors are known to be mainly expressed by B-
cells [8], we normalized the mRNA levels of BAFFR and TACI to
the mRNA levels of a B-cell specific marker CD19, the relative
mRNA expression of these two receptors appeared similar in all
groups (data not shown). We next verified the protein expression
pattern of BAFF in skin. Immunostaining indicated that the
cellular origins of BAFF in healthy skin were keratinocytes and
cells in dermis co-stained with anti-CD68 mAb (Fig. 2C). The
expression of BAFF by keratinocytes in healthy skin was confirmed
by immunostaining of human keratinocytes (Fig. 2D). However,
immunostaining for BAFFR and TACI expression on skin sections
and on cultured keratinocytes revealed that these two receptors
were not expressed by keratinocytes (data not shown). In lesional
skin of AE, APT-AE and SE, besides the keratinocytes,
subpopulations of the infiltrating CD3
+ T cells and CD68
+
macrophages also expressed BAFF, as shown by double-immuno-
staining on skin sections (Fig. 2E).
The mRNA expression of APRIL is decreased in lesional
skin of AE, APT-AE and SE
In contrast to BAFF, the relative mRNA levels of APRIL were
decreased in lesional skin of AE, APT-AE and SE, compared to
HC (Fig. 3A). Similarly, ‘‘TWE-PRIL’’, the cell surface bound
form of APRIL, showed a tendency of lower expression in lesional
skin (Fig. 3A). In healthy skin, APRIL was expressed by
keratinocytes and by cells in dermis co-stained with anti-CD3
(Fig. 3B) or anti-CD68 mAb (data not shown). We confirmed the
expression of APRIL in healthy keratinocytes by immunostaining
of cultured human keratinocytes, which showed a similar
intracellular expression pattern as found in HC skin (Fig. 3C)
and was different from the cell membrane associated staining
pattern of BAFF seen in figure 2. The expression of APRIL by
keratinocytes in lesional skin of AE and APT-AE was decreased
and among the infiltrating CD3
+ T-cells in APT-AE, only a small
subpopulation was found to express APRIL (Fig. 3B), which was in
line with the decreased mRNA expression of APRIL observed in
these inflammatory skin lesions.
The mRNA expression of Fn14 is increased in AE and
APT-AE skin lesions
Local expression of TWEAK and its receptor Fn14 have been
shown to be increased in target tissues of several diseases [13].
Here, we found a decreased mRNA expression of TWEAK in
lesional skin of AE, APT-AE and SE (Fig. 4A), whereas the mRNA
expression of Fn14 showed having an increased tendency in
lesional skin of AE, SE and APT-AE (Fig. 4A). Interestingly, the
mRNA levels of Fn14 and TWEAK positively correlated to each
other in SE, while these factors correlated inversely in AE (Fig. 4B).
Furthermore, the mRNA levels of Fn14 in APT-AE correlated
inversely with the APT scores (Fig. 4C). The protein expression
pattern of TWEAK in skin specimens from all groups was similar,
where TWEAK was expressed by keratinocytes and cells in dermis
(Fig. 4D). The expression of Fn14 was in the dermal-epidermal
basement membrane zone in both healthy skin of HC (Fig. 4D)
and skin of AE, SE and APT-AE. Primary keratinocytes in culture
did not stain with anti-TWEAK mAb and anti-Fn14 mAb (data
not shown), which suggest that the local environment is important
for their expression.
The mRNA expression of BAFF in cultured keratinocytes
is regulated by IFN-c and IL-27 and is correlated with that
of IL-18 in lesional AE skin
The correlation between the protein levels of BAFF, APRIL and
TWEAK in the circulation and mRNA levels in the skin was
analyzed, however, no correlation was found (data not shown),
suggesting that the systemic expression of these cytokines is not
connected to the levels in the local environment in eczema skin.
We and others have previously shown that the plasma level of IL-
18, a product of activation of the inflammasome, is increased in
AE patients [20,21,22]. In addition, the expression of IL-18 has
been found to be increased in inflamed skin [23]. Thus, as a
measure of local inflammation for means of correlation, we
investigated the expression of IL-18 in lesional skin of AE and SE.
IL-18 was found to be expressed at the level of the single basal
layer of keratinocytes in HC, whereas expression in the suprabasal
layers of keratinocytes was observed in lesional skin of AE, and
particularly in APT-AE and SE (Fig. 5A). The mRNA level of IL-
Table 1. Correlations between the serum/plasma levels of
BAFF, APRIL, TWEAK and SCORAD, plasma levels of total-IgE or
Malassezia-IgE in patients with AE, respectively.
Correlation R value P value
BAFF and SCORAD 20.114 0.263
BAFF and total IgE 20.179 0.078
BAFF and Malassezia-IgE 20.120 0.240
APRIL and SCORAD 0.063 0.539
APRIL and total IgE 0.130 0.202
APRIL and Malassezia-IgE 0.094 0.360
TWEAK and SCORAD 0.018 0.861
TWEAK and total IgE 20.078 0.449
TWEAK and Malassezia-IgE 20.099 0.337
Correlations were assessed with the Spearman’s rank correlation (n=97–98).
doi:10.1371/journal.pone.0022202.t001
Table 2. Characterization of patients with AE or SE and
healthy controls.
Healthy
controls AE patients SE patients
Total number of participants 58 99 27
Gender (female/male) 36/22 51/48 5/22
Age (years) 37 (18–64)
a 28 (18–65)
a 39 (22–63)
a
SCORAD - 35 (15–69)
a -
Mild AE/moderate AE/severe
AE
b
- (0/66/33) -
Plasma total IgE (kU/L) 20 (3.2–140)
a 280 (2–15100)
a 17 (2–390)
a
Plasma Malassezia-IgE 0% 60% 0%
PhadiatopH positive 0% 80% 22%
Asthma and/or rhinitis 0% 74% 22%
a) Median (range);
b) Defined according to the objective SCORAD index (range 0–83; mild ,15,
moderate=15–40, severe .40) [37].
doi:10.1371/journal.pone.0022202.t002
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AE and APT-AE (Fig. 5B, C), but not in HC and SE lesions (data
not shown). No correlation between IL-18 and TWEAK was
found (data not shown). Since we found expression of BAFF and
APRIL in healthy keratinocytes (Fig. 2D and Fig. 3C), we wanted
to investigate if this expression could be regulated by IL-18, as well
as other stimuli involved in the pathogenesis of AE. We found that
IFN-c and IL-27 dramatically increased the mRNA level of BAFF
but not that of APRIL, TWEAK and Fn14 in keratinocytes
stimulated for 24 hours (Fig. 5D). The other stimuli tested, M.
sympodialis extract, LPS, LTA (Lipoteichoic acid), TNF-a, IL-4, IL-
18 and IL-31, did not influence the mRNA levels analyzed
(Fig. 5D).
Discussion
The role of B-cells in the pathology of allergy is undisputable,
and their contribution beyond IgE production has recently started
to be appreciated [6]. However, the factors influencing B-cell
activation and homeostasis in allergic diseases, in both systemic
and target tissue environments, need to be characterized. Here, we
sought to define the role for BAFF, APRIL and TWEAK in
inflammatory skin disease by comparing the systemic levels and
skin expression in AE and SE patients as well as HCs.
Unlike other inflammatory diseases including autoimmune
diseases and asthma [8,10], we found that the circulating levels
of BAFF and APRIL were not elevated in patients with AE and
they did not correlate with AE severity and plasma levels of total
IgE or Malassezia-specific IgE. Notably, a recent publication has
shown that the serum levels of BAFF were increased in children
with AE [11], but this was not the case in adult patients [12], in
agreement with our results. These findings suggest that BAFF
might play a role at an early stage of AE but not at a later adult
stage. Indeed, this seems to be the case in the local skin
environment, where the mRNA expression of BAFF is found to
be dramatically increased in APT-AE, which mimics the acute
lesion.
Matsushita et al reported an increased level of APRIL in AE
patients compared to HCs [12], which is not found in the cohort of
patients investigated here. The reason for this is unclear, but might
suggest that larger cohorts and multiple studies are needed to settle
if levels of these factors are really altered in AE patients. On the
other hand, our results show that AE and SE, two different chronic
inflammatory skin diseases, can be distinguished by the systemic
Figure 2. Expression of BAFF in skin of HC and lesional skin of AE and SE determined by quantitative RT-PCR and
immunofluorescence. (A–B) Relative mRNA expression of BAFF, BAFFR and TACI in skin of HC (n=9), lesional skin of AE (n=9), APT-AE (n=6)
and SE (n=6). Data shown as mean 6 SEM, *p,0.05, **p,0.01, ***p,0.001 by Mann-Whitney test. (C) Representative picture of double-
immunostaining with anti-BAFF and anti-CD68 mAb on sections of skin biopsies from HC (bar=75 mm). The arrow indicates representative cells
double positive for anti-BAFF and anti-CD68 staining. (D) Immunostaining with anti-BAFF mAb on cultured human keratinocytes (bar=30 mm). (E)
Representative pictures of double-immunostaining with anti-BAFF and anti-CD68/anti-CD3 mAb on sections of lesional AE skin and APT-AE skin
specimens (bar=75 mm). The upper arrow indicates the red cells stained with only anti-CD3 mAb. The lower arrow indicates the yellow cells stained
with both anti-CD3 and anti-BAFF mAb.
doi:10.1371/journal.pone.0022202.g002
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concentration compared to HCs. The pathological role of the
decreased serum APRIL level in SE remains to be determined.
The keratinocytes in skin, besides the barrier function, can also
secrete numerous cytokines, chemokines and some of the growth
factors in an autocrine manner regulating barrier homeostasis, and
this ability of keratinocytes has been shown to be dysregulated in
AE lesional skin [24]. It is known that BAFF and APRIL can be
expressed by resident cells in several kinds of tissues [8]. We report
here that healthy keratinocytes can also synthesize and express
BAFF and APRIL, both in vivo and ex vivo, and in lesional skin of
AE, APT-AE and SE the keratinocytes have impaired APRIL
expression compared to HCs. Different from other TNF ligands,
APRIL only functions as a soluble protein. By immunohistological
analysis, we confirmed the intracellular expression pattern of
APRIL in keratinocytes both in vivo and ex vivo, which is different
from the cell membrane associated expression pattern of BAFF.
We then studied the regulation of BAFF and APRIL in vitro in
keratinocytes using some factors involved in the pathogenesis of
eczema and we found that the BAFF mRNA level was
dramatically increased by IFN-c and IL-27. IL-27 is a member
of the IL-12 family, produced by activated APCs [25]. The
increased expression of IFN-c and IL-27 in chronic eczema skin
lesions has been demonstrated before [1,25], and both IFN-c and
IL-27 have been shown to greatly induce the production of CXCL
9–11 in normal human keratinocytes [26,27], the chemokines
known to attract Th1 cells, triggering and sustaining skin
inflammation [26,27]. Here we suggest that IFN-c and IL-27
can amplify the skin inflammation not only through the regulation
of the chemokine production in keratinocytes, but also through the
regulation of BAFF expression in these cells.
By immunostaining we did not found the expression of TACI or
BAFFR by keratinocytes both in vivo and ex vivo, indicating that the
expression of BAFF and APRIL by keratinocytes is not regulated
by feedback autocrine mechanism. BAFF and APRIL thus
presumably have no regulatory role for the homeostasis of
keratinocytes. TACI and BAFFR are mainly expressed by B-cells
[8] and the presence of B-cells in normal skin and the infiltration
of B-cells in AE eczema skin have been demonstrated by Simon
et al [5]. We could detect the expression of these two receptors in
skin, however, the mRNA level of these two receptors in inflamed
skin of APT-AE, AE and SE was not found to be increased. The
reason for this could be the dilute effect by the influx of a large
number of T-cells and macrophages in inflammatory skin lesions.
Indeed, when the mRNA levels of these two receptors were
normalized to the expression level of a B-cells maker CD19, the
relative mRNA expression of TACI and BAFFR appeared similar
in all groups.
Figure 3. Expression of APRIL in skin of HC and lesional skin of AE and SE determined by quantitative RT-PCR and
immunofluorescence. (A) Relative mRNA expression of APRIL and TWE-PRIL in skin of HC (n=9), lesional skin of AE (n=9), APT-AE (n=6) and SE
(n=6). Data shown as mean 6 SEM, *p,0.05, **p,0.01 by Mann-Whitney test. (B) Representative pictures of double-immunostaining with anti-APRIL
and anti-CD3 mAb on sections of skin biopsies from HC, lesional AE skin and APT-AE skin specimens (bar=75 mm). The arrows indicate representative
yellow cells double positive for anti-CD3 and anti-APRIL staining. (C) Cultured human keratinocytes immunostained with anti-APRIL mAb
(bar=30 mm).
doi:10.1371/journal.pone.0022202.g003
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functions and receptors. Here we demonstrate that opposite to
BAFF, the expression of APRIL, as well as the cell surface APRIL
hybrid TWE-PRIL, is down-regulated in the skin lesions of APT-
AE, AE and SE. It has been shown that APRIL binding to TACI
delivers a negative signal to B-cells [28]. Since APRIL does not
bind to BAFFR, it does not deliver a BAFFR mediated positive
signal to B-cells. Therefore, the decreased expression of APRIL
and TWE-PRIL together with the increased BAFF expression in
eczema skin could contribute to a reduced negative regulatory
input on B-cells, which is more pronounced in the initiating acute
stage of AE, resulting in dysregulation of over-activated B-cells in
lesional skin of AE and SE. Our data of the down-regulation of
APRIL and the up-regulation of BAFF in the eczema skin of AE
and SE is also important for guiding potential clinical treatment.
When targeting BAFF and APRIL in the therapy for AE and SE,
the agents neutralizing only BAFF but having no effect on APRIL
might be more suitable than those targeting both BAFF and
APRIL.
The up-regulation of IL-18 in suprabasal keratinocytes in skin
lesions has been described in psoriasis [29]. Here we report that
this phenomenon is also present in APT-AE, AE and SE. Indeed,
IL-18 has been shown to play a harmful effect to enhance
inflammation in several autoimmune and inflammatory diseases
[30]. Since B-cells are known to lack the expression of the IL-18
receptor, the effect of IL-18 on B-cell related activation has not
been well studied. We suggest that there might be a direct or
indirect interplay between IL-18 and BAFF/APRIL in AE, since
the mRNA level of BAFF/APRIL correlates with that of IL-18 in
lesional skin of AE and APT-AE. A connection between these
factors is supported by a mouse model where daily i.p. injections of
IL-18 for 10 days induce production of both IgE [31,32] and
BAFF (our own unpublished observation). Furthermore, we
demonstrated that although IL-18 itself had no direct effect on
the regulation of BAFF and APRIL production in cultured
keratinocytes, IFN-c dramatically increased the BAFF mRNA
level in these cells. Since IL-18 is known to be a powerful
stimulator of IFN-c production [33], we therefore suggest that IL-
18 could be produced locally by inflammatory cells and indirectly
regulate the production of BAFF and APRIL in keratinocytes
through IFN-c.
Elevated serum levels of TWEAK have been found in patients
with chronic inflammatory diseases and been suggested to be
playing either a protective or harmful role [14]. For example, in
systemic sclerosis where TWEAK is associated with a low
frequency of pulmonary fibrosis [34] and in rheumatoid arthritis
where the levels of TWEAK reflect disease activity [35]. In our
patient cohort, we found no difference in the serum level of
TWEAK in patients with AE or SE compared with HCs. This is in
agreement with a recent study, where the serum level of TWEAK
was reported to be similar among patients with AE or psoriasis and
HCs [15]. Thus, unlike other chronic inflammatory diseases,
increased level of TWEAK is not a candidate for a systemic role in
the pathogenesis of AE and SE. Zimmermann et al also found that
the TWEAK mRNA expression in healthy keratinocytes was not
influenced by various eczema related stimuli [15] in agreement
with our results. However, although the authors found similar
mRNA expression of TWEAK between lesional and non-lesional
skin from patients with AE, they found that the protein expression
of TWEAK was only present in the epidermis of lesional, but
absent in non-lesional skin by means of immunofluorescence [15].
In the biopsy specimens used in our study we could detect
TWEAK expression not only in lesional AE skin, but also in
healthy skin by immunofluorescence and we also found altered
mRNA levels of TWEAK and Fn14 in AE lesions compared with
HC. These differences between our study and the study by
Zimmermann et al [15] could besides different immuno-staining
protocols and source of anti-TWEAK and anti-Fn14 mAb possibly
Figure 4. Expression of TWEAK in skin of HC and lesional skin of AE and SE determined by quantitative RT-PCR and
immunofluorescence. (A) Relative mRNA expression of TWEAK and Fn14 in skin of HC (n=9), lesional skin of AE (n=9), APT-AE (n=6) and SE
(n=6). Data shown as mean 6 SEM, *p,0.05, **p,0.01 by Mann-Whitney test. (B) Correlation of relative mRNA levels of TWEAK and Fn14 in AE
(n=9) and SE (n=6) skin specimens. (C) Correlation of relative mRNA levels of Fn14 and APT reaction scores in APT-AE (n=6) skin specimens. The
correlations were analyzed using Spearman’s rank correlation. (D) Representative picture of immunostaining with anti-TWEAK or anti-Fn14 mAb on
sections of skin specimens from HC (bar=75 mm).
doi:10.1371/journal.pone.0022202.g004
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from the buttock area of patients with AE or psoriasis, whereas we
used skin biopsy specimens from healthy individuals. Furthermore,
the source of the primary healthy keratinocytes was from adults in
their study [15] and from young individuals in ours, which might
lead to the different observations on the Fn14 expression in
Figure 5. Expression of IL-18 in AE, SE and HC skin determined by immunofluorescence and the regulation of mRNA expression of
BAFF, APRIL, TWEAK and Fn14 in healthy keratinocytes by IL-18 and other eczema related stimuli. (A) Representative pictures of
immunostaining with anti-IL-18 mAb on sections of skin biopsies from HC, lesional skin of AE, APT-AE and SE (bar=150 mm). (B) Correlation of relative
mRNA levels of BAFF and IL-18 in AE (n=9) and APT-AE (n=6) skin specimens. (C) Correlation of relative mRNA levels of APRIL and IL-18 in AE (n=9)
and APT-AE (n=6) skin specimens. The correlations were analyzed using Spearman’s rank correlation. (D) Relative mRNA expression of BAFF, APRIL,
TWEAK and Fn14 in healthy keratinocytes cultured for 24 h with indicated stimuli. Data are shown as mean 6 SEM (n=3) from two separate
experiments.
doi:10.1371/journal.pone.0022202.g005
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reported the protein expression of Fn14 on primary keratinocytes
by FACS analysis [16], but the culture system in this study is
different from what we used in this study; the extra supplements in
their culture media could contribute to the induction of Fn14
expression in keratinocytes ex vivo. Further studies are needed to
verify these possibilities.
It is known that the expression of Fn14 is inducible by tissues
injury and that Fn14 signalling can occur in a TWEAK-dependent
or -independent manner, contributing to tissue repair or a
pathological effect depending on different disease or injury setting
[14]. Indeed, we found that Fn14 was expressed at a low level in
healthy skin and its expression level was significantly induced in
the skin of AE and APT-AE. Importantly, we report here that in
AE lesions the mRNA level of Fn14 correlates inversely with that
of TWEAK, suggesting a compensatory mechanism that regulates
TWEAK and Fn14 expression in AE lesions, where TWEAK-
independent Fn14 signalling might be more dominate. Mean-
while, our data suggest that TWEAK-independent Fn14 signalling
is not at work in SE lesions, where the TWEAK-dependent
signalling could be more important in this setting, since the
expression levels of TWEAK and Fn14 positively correlate to each
other. Thus, we suggest that the persistent activation of Fn14
signalling in skin lesions of AE and SE could result in harmful and
pathological effects to perpetuate the diseases. Therefore blocking
TWEAK-independent and -dependent Fn14 signalling could be a
therapeutic strategy for AE and SE, respectively. Whereas we also
show here that blocking Fn14 signalling might not be suitable for
the acute phase of AE, since the expression level of Fn14 correlates
inversely with the APT score, suggesting a protective role of Fn14
signalling in acute AE. This suggestion is also supported by the
current hypothesis that TWEAK-Fn14 axis normally plays a
beneficial role in tissue repair following acute injury [14].
In conclusion, our data suggests that elevated levels of BAFF,
APRIL or TWEAK in the circulation are not a part of the
pathogenesis of AE and SE. However, the expression of these
cytokines is altered in the local inflammatory environment in
lesional skin of AE and SE. Furthermore, the expression pattern in
AE lesions can be distinguished from that of SE lesions, as well as
from that in the acute phase of AE lesions. Therefore, we propose
that BAFF, APRIL and TWEAK can be considered as potential
targets for the development of different therapeutic strategies in
these inflammatory skin disorders.
Materials and Methods
Subjects and Ethics
Adult patients with AE or SE and HCs were recruited in the
Stockholm area (Table 2). The inclusion and exclusion criteria for
the AE patients were as previously described [36]. AE disease
severity was assessed by the objective SCORAD index [37]. The
SE patients had no history of additional skin disease. The HC had
no clinical symptoms or history of allergy or skin disease. All
participants gave their written informed consent. The study was
approved by the Swedish regional ethics committee.
Atopy patch test and skin biopsy specimens
APT with an in house extract from M. sympodialis (ATCC strain
42132) [38] was performed on non-lesional skin of AE patients as
previously described [36]. The APT reaction was evaluated 48 h
later and scored from 0 to 5+ on a scale proposed by European
Task Force on Atopic Dermatitis [39]. Four mm punch skin
biopsy specimens were taken under local anaesthesia from positive
APT reactions (APT-AE), lesional skin from AE or SE patients and
normal looking skin from HC. The specimens were snap-frozen
and stored at 280uC until analysis.
Serology
The concentrations of BAFF (R&D Systems, Minneapolis, MN)
and APRIL (Bender Medsystems, Vienna, Austria) in plasma and
TWEAK (Bender MedSystems) in sera were measured by ELISA
according to the manufacturer’s instruction. Total IgE (reference
range 1.6–122 kU/L), Malassezia-specific IgE (m227, mixture of
M. sympodialis, M. globosa and M. restricta, positive$0.35 kU/L) and
specific IgE to any of 11 common aeroallergens (PhadiatopH,
positive$0.35 kU/L) were measured in plasma using Immuno-
CAP
TM (Phadia AB, Uppsala, Sweden).
Keratinocyte culture
Human keratinocytes originally isolated from skin of healthy
young boys in connection with a routine surgical operation on the
foreskin [40] were cultured in Keratinocyte-SFMH containing
5 mg/L human recombinant epidermal growth factor (EGF 1–53)
and 50 mg/L bovine pituitary extract (BPE) (GIBCOH Invitrogen
Cell Culture, Auckland, New Zealand) and 1% penicillin at 37uC
in humidified atmosphere plus 5% CO2. The third- or fourth-
passage keratinocytes were added to sterile microscope slides
(Novakemi AB, Stockholm, Sweden) and incubated overnight to
let the cells attach on the slides. The slides were then washed with
PBS, air-dried and stored at 280uC until analysis. In addition, the
keratinocytes were cultured in duplicates in 24-well plates (Becton
Dickinson, Franklin lakes, NJ) for 24 h in 700 ml culture medium
alone or stimulated with 10 mg/ml extract from M. sympodialis
(ATCC strain 42132) [38], 10 mg/ml LPS (strain O111:B4, Sigma,
St Louise, MO), 10 mg/ml Lipoteichoic acid (LTA, from
Staphylococcus aureus, Sigma), 10 ng/ml rhIFN-c (Sigma), 10 ng/
ml rhTNF-a (R&D Systems, Minneapolis, MN), 10 ng/ml rhIL-4
(Invitrogen, Camarillo, CA), 100 ng/ml rhIL-18 (MBL Interna-
tional Corporation, Woburn, MA), 100 ng/ml rhIL-27 and
100 ng/ml rhIL-31 (R&D Systems). Total RNA of the keratino-
cytes was then isolated for quantitative QT-PCR analysis (see
below).
Quantitative RT-PCR
Total RNA from cultured keratinocytes or snap-frozen skin
biopsies randomly selected from the participants (Table S1) was
isolated by the TRIzol method (Invitrogen, Carlbad, CA). Isolated
RNA was reversely transcribed by iScript TM cDNA synthesis kit
(Bio-Rad, Hercules, CA). The cDNA was quantified in duplicates
by means of real-time PCR with iQTM SYBR Green Supermix in
the iCycler iQTM Multicolor real-time detection system (Bio-
Rad). The primer sets for genes of interest were designed by
Primer-BLAST program at NCBI databases. For each primer set
(Table S2), non-template controls and melting curve were
performed to control the specificity of the amplification. Relative
expression level of a certain gene to the housekeeping gene
GAPDH was calculated with the Pfaffl-formula [41].
Immunofluorescence
Six-mm cryosections of skin biopsies and keratinocytes attached
to slides were fixed in acetone. After blocking with goat serum,
sections were incubated with primary mAb, followed by several
washes in PBS and incubation with fluorescently-labelled second-
ary Abs. The following Abs were used: anti-BAFF (Buffy-2, rat
IgM) and anti-APRIL (Aprily-8, mouse IgG1) (Axxora, Lausen,
Switzerland); anti-TWEAK (CARL-1, mouse IgG3), anti-BAFFR
(11c1, mouse IgG1), biotin conjugated anti-TACI (1A1, rat IgG2a)
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anti-IL-18 (25-2G, mouse IgG1; Medical & Biological Laborato-
ries, Naka-ku Nagoya, Japan); Alexa-488 or 546-conjugated
F(ab’)2 of goat anti-mouse IgG and Alexa-488 or 647-conjugated
goat anti-rat IgG (Invitrogen, Eugene, OR). In double-stainings,
FITC or PE-conjugated anti-CD3 (SK7, mouse IgG1;B D
biosciences, San Jose, CA) or Alexa-488-conjugated anti-CD68
(KP1, mouse IgG1; Santa Cruz Biotechnology, Heidelberg,
Germany) were used. Stainings with isotype controls were
performed to confirm the specificity of the immunostainings.
Images were acquired using a confocal laser scanning microscope
(TCS SP2; Leica Microsystems, Mannheim, Germany).
Statistical analysis
Mann-Whitney test was used to test the difference between two
groups. Correlation was assessed by Spearman’s rank correlation.
All calculations were performed by GraphPad Prism 5 software
(GraphPad Software Inc., La Jolla, CA). p,0.05 was considered
significant.
Supporting Information
Table S1 Characterization of the patients with AE or SE and
HC included in analysis of skin specimens.
(DOC)
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